Active Ingredient(s):Ranibizumab-eqrn FDA Approved: * August 2, 2022 Pharm Company: *COHERUS BIOSCIENCES INC Category:Vision / Eye Health
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Ranibizumab was developed by Genentech and marketed by them in the United States, an...
* May have multiple approval dates, manufacturers, or labelers.